Evidence map›Paper›PMID 42724965›Full record

ArticleFrontiers in toxicology2026

Readiness of the

Emanoela Thá, Antje Vennemann, Vanessa Marani, Oliver Gräb, Andreas Verlohner, Lan Ma-Hock, Inka Marie Spyridonov, Pamina Weber, Aline Chary, Tommaso Serchi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Emanoela Thá *BASF SE, Experimental Toxicology and Ecology, Ludwigshafen am Rhein, Germany.
Antje Vennemann *IBE R&D Institute for Lung Health gGmbH, Münster, Germany.
Vanessa MaraniLIST, Luxembourg Institute of Science and Technology, Esch-sur-Alzette, Luxembourg.
Oliver GräbIBE R&D Institute for Lung Health gGmbH, Münster, Germany.
Andreas VerlohnerBASF SE, Experimental Toxicology and Ecology, Ludwigshafen am Rhein, Germany.
Lan Ma-HockBASF SE, Experimental Toxicology and Ecology, Ludwigshafen am Rhein, Germany.
Inka Marie SpyridonovBASF SE, Experimental Toxicology and Ecology, Ludwigshafen am Rhein, Germany.
Pamina WeberLIST, Luxembourg Institute of Science and Technology, Esch-sur-Alzette, Luxembourg.
Aline CharyLIST, Luxembourg Institute of Science and Technology, Esch-sur-Alzette, Luxembourg.
Tommaso SerchiLIST, Luxembourg Institute of Science and Technology, Esch-sur-Alzette, Luxembourg.
Robert LandsiedelBASF SE, Experimental Toxicology and Ecology, Ludwigshafen am Rhein, Germany.
Martin WiemannIBE R&D Institute for Lung Health gGmbH, Münster, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhaled particles can induce persistent pulmonary inflammation when macrophage-mediated clearance mechanisms are overwhelmed. Distinguishing particles that trigger biological activity through intrinsic toxicity from those acting primarily via particle overload represents a central challenge in inhalation toxicology and regulatory safety assessment. Mechanistically anchored new approach methodologies (NAMs) that capture key macrophage responses may therefore provide valuable tools for particle hazard identification while reducing reliance on animal testing. The alveolar macrophage assay (AMA) was developed as an

Indexed as

alveolar macrophagesinhalation toxicityin vitro methodNAMsreproducibilityrespirable particles

Identifiers

PMID42724965
PMCPMC13561502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.